Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results

The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.